Formulary guidance and transparency from P&T to point of care


Reality Check on Hemophilia A (Factor VIII)

Market access for hemophilia A (factor VIII) treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.  

To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:

  • Payer Insights: Under the pharmacy benefit, about 34% of the lives under commercial formularies are covered with utilization management restrictions
  • Class Trends: PBMs are increasingly focused on offering high-touch condition management services that give them a more active role in patient care. For example, AscellaHealth, LLC harnesses a variety of resources to help better manage treatment for hemophilia 
  • Key Findings: The market is trending toward longer half-life recombinant products. For the most part, hemophilia products are viewed as undifferentiated brands 

What can pharma do to curb this trend and overcome these challenges?

Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.

Download the full Reality Check now.